- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03033433
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
An Open-label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 114
- Tri-Service General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Stage 1
- Adult, male or female aged between 20-40 years old;
- Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest X-rays, and electrocardiogram;
- Body Mass Index (BMI) between 18.5 and 24, inclusive, (BMI will be calculated as weight in kilogram [kg]/height in meters2 [m2]);
- Clinically normal hematology, biochemistry and urinalysis determinations based on investigator's discretion;
- Subject is willing and able to comply with study procedures and sign informed consent.
Stage 2
- Male or female aged between 20-70 years old;
- Diagnosed T2DM (WHO 1999 criteria);
- Not effective in alleviating T2DM after monotherapy of metformin 1,500mg/day [or 1,000mg/day if unable to tolerate higher dose] for 3 months
- HbA1c of 7.0 % to 9.0% (inclusive);
- BMI of at most 35 kg/m2;
- Subject is willing and able to comply with study procedures and sign informed consent
Exclusion Criteria:
Stage 1
- Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with the assessments of safety or pharmacodynamics variables during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, musculoskeletal or hematological disease as determined by the clinical judgment of the investigator;
- Subject has received any investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug;
- Subjects have taken or potentially take any prescription medication and/or over the-counter medication from within 1 week prior to the first dose of study drug to the end of study period;
- Subject has alcohol, caffeine, grapefruit juice, or nicotine consumption within 24 hours prior to the administration of study drug;
- Female subject of childbearing potential who: is lactating; or has positive urine pregnancy test at Visit 1; or refuses to adopt at least two forms of birth control (at least one of which must be a barrier method) during the study.
Stage 2
- Known or suspected allergy to any ingredients of study product
- Pregnant or lactating or premenopausal with childbearing potential but not taking at least two forms of birth control (at least one of which must be a barrier method) during the study.
Note: Acceptable forms include:
- Established use of oral, injected or implanted hormonal methods of contraception.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. 3. Participated in another clinical trial and received an investigational drug within four weeks prior to the present trial
- Impaired hepatic function defined as alanine aminotransferase (ALT), aspartate transaminase (AST) or alkaline phosphatase (ALP) at least 2.5 times upper referenced limit
- Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115 umol/L) for males and at least 1.2 mg/dL (at least 106 umol/L) for females
- With any uncontrolled illness or a history of any illness judged by the investigator that entering the trial may be detrimental to the subject
- Metformin contraindications according to the package insert
- Current treatment with systemic corticosteroids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DCB-DM101, 500 mg tablet, determination of optimal dose
Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
|
determination of optimal dose for Stage 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage 1: Optimal dose for Stage 2, dose limiting toxicity (DLT)
Time Frame: 7 months
|
Primary endpoint, DLT is defined as: Any causally related adverse event as judged by investigator is greater than or equal to Grade 2. The causality of each adverse event to investigational product will be judged by investigator during the conduction of each dosing cohort in Stage I. DSMB will reevaluate the causality of each DLT after the completion or termination of this dosing cohort judged by investigator to determine whether dose escalation or entering to stage 2 can be proceeded.Optimal Dose will be one tablet or two tablets or 4 tablets.
the optimal dose for stage 2 is defined using rules as follows but will be determined by sponsor and investigators.
|
7 months
|
Stage 2: Number of Participants with Adverse events and Serious adverse events that are related to treatment
Time Frame: 3 months
|
Specified:Primary endpoint, An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a study medication and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study medication, whether or not related to the study medication. A Serious Adverse Event is defined as an AE meeting one of the following conditions. Death during the period of protocol defined surveillance. Life threatening Event defined as a participant at immediate risk of death at the time of the event. An event requiring inpatient hospitalization or prolongation of existing hospitalization during the period of protocol defined surveillance. Results in congenital anomaly or birth defect. Results in a persistent or significant disability and incapacity. |
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage1: Number of Participants with Adverse events and Serious adverse events that are related to treatment
Time Frame: 7 months
|
Secondary endpoint, An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a study medication and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study medication, whether or not related to the study medication. A Serious Adverse Event is defined as an AE meeting one of the following conditions. Death during the period of protocol defined surveillance. Life threatening Event defined as a participant at immediate risk of death at the time of the event. An event requiring inpatient hospitalization or prolongation of existing hospitalization during the period of protocol defined surveillance. Results in congenital anomaly or birth defect. Results in a persistent or significant disability and incapacity. |
7 months
|
Stage2: Change from baseline in results of oral glucose tolerance test (OGTT)
Time Frame: 0 (pre-dose) and 0.5, 1, 1.5, 2, 2.5 hours post-dose
|
While patient takes OGTT at Screening visit, blood glucose will be monitor at right before, 0.5, 1, 1.5, and 2 hr after administration of solution containing 75 g glucose.
While at visit 2 and 4, blood glucose will be monitored at pre-dose, right before taking solution containing 75 g glucose(30 mins after dosing), 1, 1.5, 2, and 2.5 hr after administration of dose.
|
0 (pre-dose) and 0.5, 1, 1.5, 2, 2.5 hours post-dose
|
Stage2: Change from baseline in biomarker( serum insulin) testing results.
Time Frame: Visits 1 (-30 to 1 days), Visit 2 (Day 1), Visits 3 (Day 8), Visit 4(Day 14)and 5 (Day 28).
|
Biomarker consists of serum insulin.
Insulin will be measured at all the same time points where blood glucose is measured including OGTT test time points for Visits 1 (-30 to 1 days), 2 (Day 1), and 4(Day 14), and single blood sampling besides laboratory test for Visits 3 (Day 8) and 5 (Day 28).
|
Visits 1 (-30 to 1 days), Visit 2 (Day 1), Visits 3 (Day 8), Visit 4(Day 14)and 5 (Day 28).
|
Stage2: Change from baseline in biomarker( serum fructosamine) testing results.
Time Frame: Visit 1 (-30 to 1 days), Visit 3 (Day 8), Visit 4 (Day 14), and Visit 5 (Day 28).
|
Fructosamine at will be measured at Visit 1 (-30 to 1 days), Visit 3 (Day 8), Visit 4 (Day 14), and Visit 5 (Day 28).
|
Visit 1 (-30 to 1 days), Visit 3 (Day 8), Visit 4 (Day 14), and Visit 5 (Day 28).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yi-Jen Hung, MD, Tri-Service General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCB-DM101-CP001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Johns Hopkins UniversityBeth Israel Deaconess Medical CenterActive, not recruitingHypertension | Diabetes Mellitus, Type 2 | Diabetes | Diabetes type2 | Type 2 Diabetes | Type2 Diabetes | Type II Diabetes | High Blood PressureUnited States
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
University of ChicagoCompleted
-
Michigan State UniversityUniversity of Michigan; Claremont Graduate UniversityUnknown
-
University of AlbertaSherwood Park Strathcona County Primary Care Network, AlbertaCompleted
-
Brittany L SmallsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
LMC Diabetes & Endocrinology Ltd.Merck Sharp & Dohme LLC; Syreon CorporationWithdrawnType2 Diabetes
Clinical Trials on DCB-DM101
-
Yonsei UniversityRecruitingFemoropopliteal Artery DiseaseKorea, Republic of
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecruiting
-
Acotec Scientific Co., LtdShanghai Tongji Hospital, Tongji University School of MedicineRecruiting
-
C. R. BardCompletedFemoral Artery Occlusion | Femoral Artery Stenosis | Stenosis of Popliteal Arteries | Occlusion of Popliteal ArteriesChina
-
ReFlow Medical, Inc.Massachusetts General Hospital; Syntropic CorelabCompletedCritical Limb IschemiaDominican Republic
-
Acotec Scientific Co., LtdRecruitingStenosis of Native Hemodialysis Arteriovenous FistulasChina
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East AngliaRecruiting
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingCoronary Artery DiseaseChina
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece